Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.13.5521

Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer  

Shi, Bing (Department of Oncology, The Second Hospital of Nantong City)
Zhang, Xiu-Bing (Department of Oncology, The Second Hospital of Nantong City)
Xu, Jian (Department of Oncology, The Second Hospital of Nantong City)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.13, 2015 , pp. 5521-5524 More about this Journal
Abstract
Purpose: This analysis was conducted to evaluate the efficacy and safety of icotinib based regimens in treating patients with non-small cell lung cancer (NSCLC). Methods: Clinical studies evaluating the efficacy and safety of icotinib-based regimens with regard to response and safety for patients with NSCLC were identified using a predefined search strategy. Pooled response rates of treatment were calculated. Results: With icotinib-based regimens, 7 clinical studies which including 5,985 Chinese patients with NSCLC were considered eligible for inclusion. The pooled analysis suggested that, in all patients, the positive reponse rate was 30.1% (1,803/5,985) with icotinib-based regimens. Mild skin itching, rashes and diarrhea were the main side effects. No grade III or IV renal or liver toxicity was observed. No treatment-related death occurred in patients treated with icotinib-based regimens. Conclusions: This evidence based analysis suggests that icotinib based regimens are associated with mild response rate and acceptable toxicity for treating Chinese patients with NSCLC.
Keywords
Icotinib; NSCLC; chemotherapy; response rate; toxicity;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Zheng Y, Fang W, Deng J, et al (2014). Sequential treatment of icotinib after first-line pemetrexed in advanced lungadenocarcinoma with unknown EGFR gene status. J Thorac Dis, 6, 958-64.
2 Cappuzzo F, Ciuleanu T, Stelmakh L, et al (2010). Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9.   DOI   ScienceOn
3 Chen X, Zhu Q, Liu Y, et al (2014). Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study. PLoS One, 9, 95897.   DOI
4 Ellis PM, Blais N, Soulieres D, et al (2011). A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol, 6, 1379-91.   DOI
5 Feld R, Sridhar SS, Shepherd FA, et al (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review. J Thorac Oncol, 1, 367-76.   DOI
6 Fossella FV, DeVore R, Kerr RN, et al (2000). Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The tax 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol, 18, 2354-62.
7 Fukuoka M, Yano S, Giaccone G, et al (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol, 21, 2237-46.   DOI
8 Govindan R, Page N, Morgensztern D, et al. (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44   DOI
9 Gridelli C, Ciardiello F, Gallo C, et al (2012). First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol, 30, 3002-11.   DOI
10 Hanna N, Shepherd FA, Fossella FV, et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97.   DOI
11 Hotta K, Fujiwara Y, Kiura K, et al (2007) Relationship between response and survival in more than 50, 000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials. J Thorac Oncol, 2, 402-7.   DOI
12 Hu X, Han B, Gu A, et al (2014). A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Lung Cancer, 86, 207-12.   DOI
13 Jemal A, Bray F, Center MM, et al (2011) Global cancer statistics. CA Cancer J Clin, 61, 69-90   DOI
14 Leighl NB (2012). Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol, 19, 52-8.
15 Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.   DOI
16 Liu D, Jiang J, Hu P, et al (2009). Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 877, 3781-6.   DOI
17 Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.   DOI
18 National Comprehensive Cancer Network. Non Small Cell Lung Cancer. 2013, cited 2013-10-30. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
19 Pan H, Liu R, Li S, et al (2014). Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes. Cell Biochem Biophys, 70, 553-8.   DOI
20 Ramalingam SS, Dahlberg SE, Langer CJ, et al. (2008) Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol, 26, 60-5.   DOI
21 Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51.   DOI
22 Schiller JH, Harrington D, Belani CP, et al (2002). On behalf of the eastern cooperative oncology group comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.   DOI
23 Soda M, Choi YL, Enomoto M, et al (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-6.   DOI
24 Shao L, Zhang B, He C, et al (2014). Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancerafter failure of chemotherapy. Chin Med J (Engl), 127, 266-71.
25 Shepherd FA, Dancey J, Ramlau R, et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
26 Shepherd FA, Rodrigues PJ, Ciuleanu T, et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32.   DOI
27 Tan F, Shen X, Wang D, et al (2012). Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 76, 177-182.   DOI
28 Kris MG, Natale RB, Herbst RS, et al (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290, 2149-2158.   DOI
29 Yang X, Zhang H, Qin N, et al (2013). Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma. Zhongguo Fei Ai Za Zhi, 16, 364-8.
30 Zhao Q, Shentu J, Xu N, et al (2011). Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer, 73, 195-202.   DOI
31 Zheng X, Liu G, Wang S, et al (2014). A new receptor tyrosine kinase inhibitor, icotinib, for patients with lung adenocarcinomacancer without indication for chemotherapy. Oncol Lett, 8, 1563-6.